E. Aynsley

James Cook University Hospital — United Kingdom

Medicine · Health Sciences

6h-index2.1kcitations33works15.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(12), Lung Cancer Diagnosis and Treatment(11), Head and Neck Cancer Studies(8), Advanced Radiotherapy Techniques(5), Hepatocellular Carcinoma Treatment and Prognosis(4)

Publications32 total

1317O Results from CompARE phase III RCT: Neoadjuvant durvalumab plus chemoradiotherapy (CRT) followed by adjuvant durvalumab immunotherapy (IO) vs CRT alone in intermediate and high-risk oropharyngeal cancer (OPC)
Annals of Oncology·2025· 1 cited
Corrigendum to “84 Outcomes of Durvalumab after Chemoradiotherapy in Unresectable NonSmall-Cell Lung Cancer” [Lung Cancer 200 (Supplement 1) (February 2025) 108194]
Lung Cancer·2025Open Access
Head and Neck Cancer: United Kingdom National Multidisciplinary Guidelines, Sixth Edition
The Journal of Laryngology & Otology·2024· 45 citedOpen Access
CompARE: study protocol for a phase III randomised controlled platform trial comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer
Trials·2024· 16 citedOpen Access
Randomized Phase 3 Trial of the Hypoxia Modifier Nimorazole Added to Radiation Therapy With Benefit Assessed in Hypoxic Head and Neck Cancers Determined Using a Gene Signature (NIMRAD)
International Journal of Radiation Oncology*Biology*Physics·2023· 19 citedOpen Access
Survival outcomes for patients with nasopharyngeal carcinoma in non–endemic region in the UK treated with intensity modulated based radiotherapy 65 Gy in 30 fractions ± weekly cisplatin chemotherapy
Reports of Practical Oncology & Radiotherapy·2022· 3 citedOpen Access
OC-0533 Two Centre Feasibility study of single fraction lung stereotactic ablative radiotherapy (SABR)
Radiotherapy and Oncology·2021
P-187 Regional Audit of the use of Nivolumab for Recurrent Head and Heck Squamous Cell Carcinoma
Oral Oncology·2021
Long-term Overall Survival Outcomes in Patients with Early Stage, Peripherally Located, Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiotherapy in a Non-academic Cancer Centre
Clinical Oncology·2020· 5 cited
PO-0988: Is there a learning curve for SABR that affects overall survival outcomes in early stage NSCLC?
Radiotherapy and Oncology·2020
A regional experience of advanced, non-squamous, ALK positive patients: their treatment and outcomes
Lung Cancer·2020
The experience of immunotherapy in lung cancer: an audit of patients receiving first-line immunotherapy for metastatic small cell lung cancer in South Tees between June 2016 and December 2017
Lung Cancer·2019
Audit of outcomes of patients with stage III NSCLC (TNM VII) who were treated with radical RT or high-dose palliative radiotherapy between January 2017 and July 2017
Lung Cancer·2019
The experience of immunotherapy in lung cancer: an audit of immunotherapy use as second-line treatment for metastatic non-small cell lung cancer (NSCLC) in the South Tees region
Lung Cancer·2019
Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial
The Lancet·2018· 989 citedOpen Access
Cetuximab versus cisplatin in patients with HPV-positive, low risk oropharyngeal cancer, receiving radical radiotherapy
Annals of Oncology·2018· 6 citedOpen Access
Outcomes of a Series of 237 Patients with Early Stage Peripheral NSCLC, Treated by SABR in a Single Institution Non-academic Setting
Clinical Oncology·2018
Stereotactic ablative radiotherapy for early stage, medically inoperable NSCLC – outcomes from a single non-academic centre in the UK
Lung Cancer·2018
Emergency presentation of lung cancer patients via A&E increases the chances of having advanced disease stage and worse performance status
Lung Cancer·2017
139: Radical re-irradiation for localised recurrence in lung cancer patients – A single centre experience
Lung Cancer·2017
page 1 of 2Next →

Frequent Co-authors

C. Peedell(18), S. Masinghe(9), T. Mansy(6), A. Hartley(5), Anthony Kong(5), R. Molerón(5), Christopher D. Huntley(5), Kristin E. Burke(5), Hisham Mehanna(4), Mehmet Şen(4), L. O’Toole(4), Devraj Srinivasan(4), Paul Nankivell(4), J. Veeratterapillay(4), Jim Daniel(4), Andrew D. Greenhalgh(4), J. Green(4), John M. Reynolds(4), David Shakespeare(4), Tessa Fulton‐Lieuw(3)